natgillin/translations-raw huggingface dataset:
Co-administration of posaconazole with proton pump inhibitors should be avoided if possible. 
Sočasni uporabi posakonazola in zaviralcev protonske črpalke se je treba izogibati, če je le mogoče.
Each dose of Noxafil should be administered during or immediately after a meal, or a nutritional supplement in patients who cannot tolerate food to enhance the oral absorption and to ensure adequate exposure. 
Bolniki, ki ne prenašajo hrane, naj zdravilo vzamejo med ali takoj po zaužitju prehranskega dodatka, da bi povečali peroralno absorpcijo in zagotovili zadostno izpostavljenost zdravilu.
Two different dosing groups were evaluated in Cohorts 1 and 2: 200 mg twice daily on Day 1, followed by 200 mg once daily thereafter (Cohort 1) and 300 mg twice daily on Day 1, followed by 300 mg once daily thereafter (Cohort 2). 
V kohortah 1 in 2 so ocenili skupini z dvema različnima odmerjanjema: 200 mg dvakrat na dan 1. dan in nato 200 mg enkrat na dan (kohorta 1) ter 300 mg dvakrat na dan 1. dan in nato 300 mg enkrat na dan (kohorta 2).
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (1.7 times the 400-mg twice daily regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 times the 400-mg twice daily regimen). 
Posakonazol ni vplival na plodnost podganjih samcev v odmerkih do 180 mg/kg (1,7-krat 400 mg režim dvakrat na dan, ki temelji na plazemskih koncentracijah v stanju dinamičnega ravnovesja pri zdravih prostovoljcih) ali podganjih samic v odmerku do 45 mg/kg (2,2-krat 400 mg režim dvakrat na dan).
After oral administration, posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. 
Po peroralni uporabi je posakonazol povečal Cmax rifabutina za 31 % in AUC rifabutina za 72 %.
11 of 16 patients were successfully treated (at the end of treatment complete or partial resolution of signs and symptoms present at baseline) with posaconazole oral suspension 800 mg/day in divided doses for a median of 296 days and up to 460 days. 
11 od 16 bolnikov so uspešno zdravili (ob koncu zdravljenja popolno ali delno izginotje izhodiščnih znakov in simptomov) s peroralno suspenzijo posakonazola 800 mg/dan v deljenih odmerkih.
H2 receptor antagonists and proton pump inhibitors No clinically relevant effects were observed when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors. 
Antagonisti receptorjev H2 in zaviralci protonske črpalke Med sočasno uporabo tablet posakonazola in antacidov, antagonistov receptorjev H2 in zaviralcev protonske črpalke niso opazili klinično pomembnih učinkov.
Hyperglycaemia, hypoglycaemia 
hiperglikemija, hipoglikemija
It should be noted that the relationship between sirolimus trough concentration and AUC is changed during coadministration with posaconazole. 
Zavedati se je treba, da se med sočasno uporabo sirolimusa in posakonazola spremeni razmerje med najnižjo koncentracijo sirolimusa in njegovo AUC.
Pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats. 
V 2-letni študiji na podganah so opažali pljučno fosfolipidozo, ki je povzročila dilatacijo in obstrukcijo alveolov.
If you think that you may have taken too much Noxafil, talk to a doctor or go to the hospital straight away. 
Če ste vzeli večji odmerek zdravila Noxafil, kot bi smeli Če menite, da ste vzeli preveč zdravila Noxafil, se takoj posvetujte z zdravnikom ali pojdite v bolnišnico.
Study 1899 was a randomised, evaluator-blinded study of posaconazole oral suspension (200 mg three times a day) versus fluconazole suspension (400 mg once daily) or itraconazole oral solution (200 mg twice a day) in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukaemia or myelodysplastic syndromes. 
Študija 1899 je bila randomizirana, za ocenjevalce slepa študija, ki je primerjala uporabo peroralne suspenzije posakonazola (200 mg trikrat na dan) in suspenzije flukonazola (400 mg enkrat na dan) ali peroralne raztopine itrakonazola (200 mg dvakrat na dan) pri bolnikih z nevtropenijo, ki so prejemali citotoksično kemoterapijo zaradi akutne mieloične levkemije ali mielodisplastičnih sindromov.
c: In 1899, this was the period from randomisation to 100 days post-randomisation; in 316 it was the period from the baseline day to 111 days post-baseline. 
c: V študiji 1899 je bilo to obdobje od randomizacije do 100. dne po randomizaciji, v študiji 316 pa od začetka študije do
What Noxafil looks like and contents of the pack Noxafil concentrate for solution for infusion is a clear, colourless to yellow liquid. 
Zdravilo Noxafil koncentrat za raztopino za infundiranje je bistra, brezbarvna do rumena tekočina.
Caution is advised during coadministration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced. 
Med sočasno uporabo posakonazola in intravensko danih substratov CYP3A4 je potrebna previdnost in po potrebi zmanjšanje odmerka substrata CYP3A4.
If you are a woman who could become pregnant you should use effective contraception while you are using Noxafil. 
Če ste ženska v rodni dobi, morate med uporabo zdravila Noxafil uporabljati učinkovito kontracepcijo.
haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura, pancytopenia, coagulopathy, haemorrhage 
hemolitično-uremični sindrom, trombotična trombocitopenična purpura, pancitopenija, koagulopatija, krvavitev
Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies. 
V študijah klinične učinkovitosti so poročali o klinično pomembnih interakcijah, ki so zahtevale sprejem v bolnišnico in/ali ukinitev posakonazola.
In a study (Study 03579) of 136 neutropenic paediatric patients 11 months - 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the pre-specified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL) (see section 5.2). 
V študiji (študija 03579) pri 136 nevtropeničnih pediatričnih bolnikih, starih od 11 mesecev do 17 let, zdravljenih s peroralno suspenzijo posakonazola v odmerkih do 18 mg/kg/dan, razdeljenih na tri odmerke dnevno, je približno 50 % bolnikov doseglo vnaprej določen cilj (povprečna koncentracija v stanju dinamičnega ravnovesja (Cav) 7. dan med 500 ng/ml in 2.500 ng/ml) (glejte poglavje 5.2).
In a study of 136 neutropenic paediatric patients 11 months - 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the pre-specified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL). 
V študiji pri 136 nevtropeničnih pediatričnih bolnikih, starih od 11 mesecev do 17 let, zdravljenih s peroralno suspenzijo posakonazola v odmerkih do 18 mg/kg/dan, razdeljenih na tri odmerke dnevno, je približno 50 % bolnikov doseglo vnaprej določen cilj (Cav 7. dan med 500 ng/ml in 2.500 ng/ml).
Similarly, administration of 400 mg posaconazole with esomeprazole (40 mg daily) decreased mean Cmax and AUC by 46 % and 32 %, respectively, compared to dosing with 400 mg posaconazole alone. 
Podobno sta se pri jemanju 400 mg posakonazola z esomeprazolom (40 mg na dan) v primerjavi z jemanjem samega posakonazola v odmerku 400 mg zmanjšali srednja vrednost Cmax oz. srednja vrednost AUC za 46 % oz. 32 %.
Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC04. 
Farmakoterapevtska skupina: antimikotiki za sistemsko zdravljenje, derivati triazola.
• breast pain 
• bolečine v dojkah
The subject population in Cohort 3 included: 1) patients with AML or MDS who had recently received chemotherapy and had developed or were anticipated to develop significant neutropenia, or 2) patients who had undergone a HSCT and were receiving immunosuppressive therapy for prevention or treatment of GVHD. 
Populacija preiskovancev v kohorti 3 je vključevala: 1) bolnike z AML ali MDS, ki so nedavno prejemali kemoterapijo in se jim je pojavila, ali je bilo pričakovano, da se jim bo pojavila pomembna nevtropenija, oziroma 2) bolnike, ki so imeli opravljeno presaditev hematopoetskih matičnih celic (HSCT) in so prejemali imunosupresivno zdravljenje za preprečevanje ali zdravljenje GVHD.
Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL). 
Po uporabi 800 mg posakonazola na dan v deljenih odmerkih za zdravljenje invazivnih glivnih okužb je bila povprečna najmanjša plazemska koncentracija pri 12 bolnikih, starih od 8 do 17 let (776 ng/ml), podobna kot pri 194 bolnikih, starih od 18 do 64 let (817 ng/ml).
• low level of platelets (thrombocytopenia) shown in blood tests - this may lead to bleeding 
• nizko število trombocitov (trombocitopenija), ki se pokaže na preiskavah krvi - povzroči lahko krvavitve
Two different dosing groups were evaluated: 200 mg twice daily on Day 1, followed by 200 mg once daily thereafter (Part IA) and 300 mg twice daily on Day 1, followed by 300 mg once daily thereafter (Part 1B and Part 2). 
Ocenili so skupini z dvema različnima odmerjanjema: 200 mg dvakrat na dan 1. dan in nato 200 mg enkrat na dan (del IA) in 300 mg dvakrat na dan 1. dan in nato 300 mg enkrat na dan (del IB in del 2).
Phenytoin (200 mg once a day) decreased the Cmax and AUC of posaconazole by 41 % and 50 %, respectively. 
Fenitoin (200 mg enkrat na dan) je zmanjšal Cmax posakonazola za 41 %, njegovo AUC pa za 50 %.
• stuffy nose 
• zamašen nos
Noxafil oral suspension and tablets are NOT interchangeable. 
Noxafil peroralna suspenzija NI medsebojno zamenljiva z Noxafil tabletami.
• low magnesium levels - shown up in blood tests 
• nizka koncentracija magnezija - pokaže se na preiskavah krvi
torsade de pointes, sudden death, ventricular tachycardia, cardio-respiratory arrest, cardiac failure, myocardial infarction 
torsades de pointes, nenadna smrt, ventrikularna tahikardija, zastoj srca in dihanja, srčno popuščanje, miokardni infarkt
• low levels of “neutrophils” a type of white blood cell (neutropenia) - this can make you more likely to get infections and be shown up in blood tests 
• nizko število nevtrofilcev - vrste belih krvnih celic (nevtropenija) - ki lahko poveča tveganje za okužbe in se pokaže na preiskavah krvi
BOTTLE LABEL 
NALEPKA NA STEKLENIČKI
Sixteen patients 8-17 years of age were treated with posaconazole oral suspension 800 mg/day in a study for invasive fungal infections (Study 0041). 
Šestnajst bolnikov, starih od 8 do 17 let, so v študiji invazivnih glivnih okužb zdravili s peroralno suspenzijo posakonazola v odmerku 800 mg/dan (študija 0041).
Do not use Noxafil if any of the above apply to you. 
Ne uporabljajte zdravila Noxafil, če kaj od naštetega velja za vas.
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (2.8 times the exposure achieved from a 300 mg intravenous dose in human) or female rats at a dose up to 45 mg/kg (3.4 times the exposure from a 300 mg intravenous dose in patients). 
Posakonazol ni vplival na plodnost podganjih samcev v odmerkih do 180 mg/kg (2,8-krat tolikšna izpostavljenost, kot je dosežena z intravenskim odmerkom 300 mg pri človeku) ali podganjih samic v odmerku do 45 mg/kg (3,4-krat tolikšna izpostavljenost kot z intravenskim odmerkom 300 mg pri bolnikih).
Clinical success rates in Oropharyngeal Candidiasis Endpoint 
Klinična uspešnost pri orofaringealni kandidozi Opazovani dogodek
The most frequently reported serious related adverse reactions included nausea, vomiting, diarrhoea, pyrexia, and increased bilirubin. 
Med najpogosteje poročanimi resnimi, z zdravilom povezanimi neželenimi učinki so bili navzea, bruhanje, driska, zvišana telesna temperatura in zvišana raven bilirubina.
• swelling of lymph glands (lymphadenopathy) 
• oteklost bezgavk (limfadenopatija)
The table below shows the recommended dose and length of treatment which depend on the type of infection that you have and may be individually adapted for you by your doctor. 
Spodnja preglednica prikazuje priporočeni odmerek in trajanje zdravljenja glede na vrsto okužbe, ki jo imate.
• pneumonia - signs include feeling short of breath and producing discoloured phlegm 
• pljučnica - med znaki so občutek težkega dihanja in izkašljevanje obarvane sluzi
Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1 
Rezistentne invazivne glivne okužbe/bolniki z rezistentno glivno okužbo, ki ne prenašajo zdravljenja 1. izbora
The recommended dose is 200 mg (one 5 mL spoonful) taken four times daily. 
Priporočeni odmerek je 200 mg (ena polna 5 ml žlička) štirikrat na dan.
• feeling weak, dizzy, tired or sleepy 
• šibkost, omotičnost, utrujenost ali zaspanost
C-posaconazole as oral suspension, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose). 
Po uporabi C-posakonazola v obliki peroralne suspenzije se je radioaktivnost pojavila predvsem v blatu (77 % radioaktivno označenega odmerka); glavni del tega je bila matična spojina (66 % radioaktivno označenega odmerka).
• abnormal skin sensations, such as numbness, tingling, itching, creeping, pricking or burning 
• nenormalne zaznave na koži, na primer omrtvelost, mravljinčenje, srbenje, gomazenje, zbadanje ali pekoč občutek
Effect of food on oral absorption in healthy volunteers The absorption of posaconazole was significantly increased when posaconazole 400 mg (once daily) was administered during and immediately after the consumption of a high fat meal (~ 50 grams fat) compared to administration before a meal, with Cmax and AUC increasing by approximately 330 % and 360 %, respectively. 
Vpliv hrane na peroralno absorpcijo pri zdravih prostovoljcih Absorpcija posakonazola se je bistveno povečala, če so bolniki zaužili posakonazol v odmerku 400 mg (enkrat na dan) ob obroku z veliko količino maščob (~ 50 gramov maščobe) oziroma takoj po takšnem obroku, v primerjavi z jemanjem zdravila pred obrokom.
How to use Noxafil 
Kako uporabljati zdravilo Noxafil
Noxafil concentrate for solution for infusion should be inspected visually for particulate matter prior to administration. 
Zdravilo Noxafil koncentrat za raztopino za infundiranje je treba pred uporabo pregledati, da ne vsebuje delcev.
Do not use Noxafil 
Ne uporabljajte zdravila Noxafil
Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients. 
Plazemske koncentracije posakonazola se lahko po uporabi tablet pri nekaterih bolnikih sčasoma povečajo.
The recommended dose is 300 mg twice a day on the first day, then 300 mg once a day, thereafter. 
Priporočeni odmerek je 300 mg dvakrat na dan prvi dan in nato 300 mg enkrat na dan.
Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly. 
Koncentracijo sirolimusa je treba izmeriti ob uvedbi zdravljenja, med sočasno uporabo in tudi ob ukinitvi zdravljenja s posakonazolom in po potrebi ustrezno prilagoditi odmerke sirolimusa.
Lactated Ringer's solution 5 % dextrose with Lactated Ringer's solution 4.2 % sodium bicarbonate 
Zdravila Noxafil se ne sme razredčiti z: raztopino Ringerjevega laktata 5 % glukozo z raztopino Ringerjevega laktata 4,2 % raztopino natrijevega hidrogenkarbonata
Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomisation, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P= 0.0354) as well as IFI-related deaths (P = 0.0209). 
Ta koristen vpliv na preživetje so dokazali, ko so v analizi upoštevali vse vzroke smrti (p = 0,0354), pa tudi smrti, povezane z invazivno glivno okužbo (p = 0,0209).
Maximum duration of exposure to the concentrate for solution for infusion was shorter than with the oral suspension. 
Najdaljša izpostavljenost zdravilu v koncentratu za raztopino za infundiranje je bila krajša kot izpostavljenost zdravilu v obliki peroralne suspenzije.
It is, therefore, suggested to closely monitor for breakthrough fungal infections in patients weighing more than 120 kg. 
Zato je bolnike, ki tehtajo več kot 120 kg, priporočljivo skrbno spremljati glede prebijajočih glivnih okužb.
Do not take Noxafil 
Ne jemljite zdravila Noxafil
Do not take Noxafil if you are pregnant unless you are told to by your doctor. 
Če ste noseči, ne jemljite zdravila Noxafil, razen če vam to naroči zdravnik.
Each mL contains 18 mg of posaconazole. 
En mililiter vsebuje 18 mg posakonazola.
Thereafter blood levels of ciclosporin should be monitored carefully during co-administration, and upon discontinuation of posaconazole treatment, and the dose of ciclosporin should be adjusted as necessary. 
Potem je treba natančno spremljati koncentracije ciklosporina v krvi, in sicer med sočasno uporabo in po prenehanju zdravljenja s posakonazolom; odmerek ciklosporina je treba prilagoditi, kot je potrebno.
Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 1.4-fold and 4.6-fold greater, respectively, than those achieved with the human therapeutic doses. 
Zvišan sistolični in arterijski krvni tlak (do 29 mmHg) so opažali pri podganah oz. opicah pri sistemskih izpostavljenostih, ki so bile 1,4-krat oz. 4,6-krat večje od izpostavljenosti, doseženih s terapevtskimi odmerki pri človeku.
There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea). 
Za bolnike s hudimi motnjami v delovanju prebavil (npr. s hudo drisko) je na voljo malo farmakokinetičnih podatkov.
Musculoskeletal and connective tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Občasni:
If you are not sure, talk to your doctor or pharmacist before taking Noxafil. 
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Noxafil.
Serial PK samples were collected on Day 1 and at steady-state on Day 8 for all Part 1 subjects and a subset of Part 2 subjects. 
Zaporedne farmakokinetične vzorce so vzeli 1. dan in v stanju dinamičnega ravnovesja 8. dan, in sicer vsem preiskovancem iz dela 1 in podskupini preiskovancev iz dela 2.
Take 200 mg (one 5 mL spoonful) three times a day. 
Jemljite 200 mg (eno polno 5 ml žličko) trikrat na dan.
Noxafil should be administered with caution to patients with pro-arrhythmic conditions such as: 
Zdravilo Noxafil je treba uporabljati previdno pri bolnikih z bolezenskimi stanji, ki povečajo nagnjenost k motnjam srčnega ritma, kot so:
thrombocytopenia, leukopenia, anaemia, eosinophilia, lymphadenopathy, splenic infarction 
trombocitopenija, levkopenija, anemija, eozinofilija, limfadenopatija, vranični infarkt
Noxafil is also available as 100 mg gastro-resistant tablet and 300 mg concentrate for solution for infusion. 
Zdravilo Noxafil je na voljo tudi v obliki 100-miligramskih gastrorezistentnih tablet in 300-miligramskega koncentrata za raztopino za infundiranje.
Excipients: Betadex Sulfobutyl Ether Sodium (SBECD), disodium edetate, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections. 
Pomožne snovi: natrijev sulfobutileter betaciklodekstrin (SBECD), dinatrijev edetat, klorovodikova kislina in natrijev hidroksid (za prilagoditev pH), voda za injekcije
Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. 
Za uporabo pri orofaringealni kandidozi glejte povzetek glavnih značilnosti zdravila Noxafil peroralna suspenzija.
There is no experience with overdose of posaconazole tablets. 
Izkušenj s prevelikim odmerjanjem tablet posakonazola ni.
Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients (see section 5.2). 
Koncentracije posakonazola v plazmi se lahko po uporabi tablet pri nekaterih bolnikih sčasoma povečajo (glejte poglavje 5.2).
• infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; 
• okužb, ki jih povzročajo glive iz družine Aspergillus in ki se niso izboljšale med zdravljenjem s protiglivnima zdraviloma amfotericin B ali itrakonazol, ali če je bilo treba ti dve zdravili ukiniti;
Intravenous use after dilution 
intravenska uporaba po razredčenju viala za enkratno uporabo
See also below regarding the effect of posaconazole on rifabutin plasma levels. 
Glede vpliva posakonazola na koncentracije rifabutina v plazmi glejte tudi spodaj.
Control Proportion (%) of patients with proven/probable Aspergillosis On-treatment period 
Kontrolna skupina Odstotek (%) bolnikov z dokazano oziroma verjetno aspergilozo Obdobje zdravljenja
There is no paediatric experience with posaconazole concentrate for solution for infusion (see sections 4.2 and 5.3). 
Izkušenj s posakonazolom v koncentratu za raztopino za infundiranje pri pediatričnih bolnikih ni (glejte poglavji 4.2. in 5.3).
• low level of “leukocytes” a type of white blood cell (leukopenia) shown in blood tests - this can make you more likely to get infections 
• nizko število levkocitov - belih krvnih celic (levkopenija) - pokaže se na preiskavah krvi; poveča lahko verjetnost za okužbe
Each vial contains 300 mg of posaconazole. 
Ena viala vsebuje 300 mg posakonazola.
Following administration of 800 mg per day of posaconazole oral suspension as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 817 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age 
Po uporabi peroralne suspenzije posakonazola 800 mg na dan v deljenih odmerkih za zdravljenje invazivnih glivnih okužb je bila povprečna najmanjša plazemska koncentracija pri 12 bolnikih, starih od 8 do 17 let (776 ng/ml), podobna kot pri 194 bolnikih, starih od 18 do 64 let (817 ng/ml).
Monitoring of patients with severe renal impairment Due to the variability in exposure, patients with severe renal impairment should be monitored closely for breakthrough fungal infections (see sections 4.2 and 5.2). 
Zaradi razlik v izpostavljenosti je treba bolnike s hudo okvaro ledvic skrbno spremljati glede prebijajočih (breakthrough) glivnih okužb (glejte poglavji 4.2 in 5.2).
nausea vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth, flatulence, constipation, anorectal discomfort 
navzea bruhanje, bolečine v trebuhu, driska, dispepsija, suha usta, flatulenca, zaprtje, anorektalno nelagodje
Paediatric population There is no paediatric experience for posaconazole tablets. 
Pediatrična populacija Izkušenj s tabletami posakonazola pri pediatričnih bolnikih ni.
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function. 
Po enkratnem peroralnem odmerku 400 mg peroralne suspenzije posakonazola pri bolnikih z blago (razred A po Child-Pughu), zmerno (razred B po Child-Pughu) ali hudo okvaro jeter (razred C po Child-Pughu) (po šest bolnikov na skupino) je bila povprečna AUC od 1,3- do 1,6- krat večja kot pri odgovarjajočih preiskovancih iz kontrolne skupine, ki so imeli normalno delovanje jeter.
No difference in the incidence of brain ventricle enlargement between control and treated animals was observed following the subsequent 5-month treatment-free period. 
Po nadaljnjem 5-mesečnem obdobju brez zdravila med kontrolno skupino živali in skupino, ki je dobivala zdravilo, niso opazili razlike v pojavnosti povečanja možganskih prekatov.
• inflammation of the blood vessels 
• vnetje krvnih žil